A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Peresolimab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RESOLUTION-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Jan 2025 Status changed from active, no longer recruiting to completed.
- 09 Dec 2024 Planned End Date changed from 23 Jan 2025 to 1 Jan 2025.
- 31 Aug 2023 Status changed from recruiting to active, no longer recruiting.